Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BR6002 (Aspirin + Rabeprazole) vs Co-administration in Healthy Volunteers
NCT05959499Phase 1Completed
- Sponsor
- Boryung
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aspirin and rabeprazole in gastric ulcer and duodenal ulcer (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Concentration-Time Curve over the Dosing Interval and Maximum Plasma Concentration. Started Jul 2023; status: completed.
02
Drugs
aspirinrabeprazole
03
Conditions
gastric ulcerduodenal ulcer
Beyond the preview
Go deeper on NCT05959499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05959499.